Samsung Galaxy A70 launched in India with 6.7-inch display, Snapdragon 675: Price in India, release dateSamsung has launched its latest Galaxy A device in India. The Galaxy A70 brings a tall Super AMOLED display, a Snapdragon chipset and a large battery, along with 25W fast charging support and Samsung Pay. Sanket Vijayasarathy New DelhiApril 17, 2019UPDATED: April 18, 2019 09:33 IST HIGHLIGHTSThe Galaxy A70 price in India has been set at Rs 28,990.The Galaxy A70 sports a large 6.7-inch AMOLED display, supports 25W fast charging and Samsung Pay.The device will go on sale starting May 1 via offline retailers and Flipkart.The Galaxy A70 has been launched in India and is the latest addition to the ever-growing Galaxy A-series. The mid-range smartphone has been official for a few weeks and was recently announced at Samsung’s “A Galaxy Event” in Bangkok. It touts a large 6.7-inch Super AMOLED display, Snapdragon 675 chipset and a large 4,500mAh battery, among other things.Samsung has so far launched the Galaxy A50 (Review), Galaxy A30 (Review), Galaxy A20 and Galaxy A10 in India that are priced between Rs 5,000 to Rs 20,000. With the Galaxy A70, Samsung has launched its first sub-Rs 30,000 phone in the country this year as it aims to deliver a premium, high-end experience. The company has also confirmed that the Galaxy A80 will launch in India in May.Galaxy A70 price in India and release dateThe Galaxy A70 price in India has been set at Rs 28,990. The phone will be up for pre-orders between April 20 to April 30. Customers who pre-order the Galaxy A70 will receive a Samsung U Flex Bluetooth headphones worth Rs 3,799 for Rs 999.Samsung’s latest Galaxy A device will go on sale starting May 1 in White, Blue and Black prism colours. The Galaxy A70 will be available across retail stores, Samsung e-Shop and Samsung Opera House. It will also be available online via Flipkart.Galaxy A70 specificationsThe Galaxy A70 is one of the biggest Galaxy A phones launched till date with a large 6.7-inch display. Samsung is using an Infinity-U Super AMOLED display with a a FHD+ (2400×1080) resolution. It supports Widevine L1 certification and the phone is also equipped with Dolby Atmos surround sound support for headphones.advertisement The Galaxy A70 sports a 3D glasstic design on the back that will come in three colours – white, blue and black. The colours offer a prism effect as well, which is similar to the Galaxy A50. The phone also supports optical in-display fingerprint sensor and face unlock.Powering the Galaxy A70 is an octa-core Snapdragon 675 chipset paired with 6GB and 128GB of internal storage, which is expandable up to 512GB via a microSD card. The handset ships with One UI based on Android Pie, which means you can expect a redesigned interface for easier one-handed use and Night Mode, among other things.The triple camera setup on the Galaxy A70 includes a 32MP primary camera with f/1.7 aperture, an 8MP ultra wide-angle camera and a 5MP depth camera. The camera also supports super slo-mo video recording and Scene Optimiser. Up front, the Galaxy A70 sports a 32MP selfie camera with f/2.0 aperture.Notably, the Galaxy A70 houses a large 4,500mAh battery and it is the first Samsung phone in India to support 25W fast charging over USB Type-C. The handset also comes with Samsung Pay secured by Knox.ALSO READ | Samsung Galaxy A70 quick review: Has the goods to make it a winner in IndiaGet real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted bySanket Vijayasarathy Tags :Follow SamsungFollow Galaxy A70
A leading Canadian scientist has developed a synthetic compound that appears to be capable of killing cancer cells while leaving healthy cells intact.Brock University chemist Tomas Hudlicky has created and patented several variations of the compound pancratistatin, which has been tested on 20 different types of cancer cells by a research team at the University of Windsor. The team’s paper, “Cancer Cell Mitochondria Targeting by Pancratistatin Analogs is Dependent on Functional Complex II and III,” appeared in the February issue of Scientific Reports.Scientists have known for some time that pancratistatin (PST), a substance found in the spider lily, causes cancer cells to die. But the low rate of natural production (a kilogram of spider lily produces less than 2 mg of PST) is a major challenge to research and clinical advancement.Hudlicky is the Tier 1 Canada Research Chair in biocatalysis — the use of biological methods to manufacture chemicals — and one of North America’s top organic researchers. His previous breakthroughs in green chemistry have led to more efficient and environmentally conscious ways to create synthetic versions of morphine and other natural drugs.He has spent more than 25 years researching PST’s chemical structure and constructing molecules that had similar structures and functions.“The aim is to make the new and active derivatives available for the manufacture of anti-cancer drugs,” says Hudlicky, a Professor of Chemistry at Brock.A key part of the construction of new drugs involves manufacturing what are known as “unnatural derivatives” of natural compounds such as PST or narciclasine, a congener of PST that is more available from natural sources. These derivatives are available through chemical synthesis from Hudlicky’s laboratory. What Hudlicky and other chemists do is to artificially enhance a natural compound’s properties through synthesis of derivatives.The Windsor research team found that Hudlicky’s PST derivatives target a cancer cell’s mitochondria, a structure within a cell responsible for respiration, energy production and cell apoptosis (or programed cell death). Current cancer treatments tend to attack DNA in both cancerous and healthy cells, but mitochondria is specific to each cell and can therefore be more precise as a target.Hudlicky says it’s still not clear how and why PST brings about cell death, but said some of the new synthetic derivatives made in his laboratory “are actually more potent and more bioavailable than the natural compounds.”‘Bioavailability’ measures how much of a substance such as a drug is absorbed into a living system and how quickly it is absorbed.Hudlicky is continuing with research on discovering and manufacturing anti-cancer compounds that can be used in drugs to treat the disease. With funding from the Natural Sciences and Engineering Research Council and a Canadian pharmaceutical company, he is developing derivatives of Amaryllidaceae alkaloids, some of which are isolated from daffodils and snowdrops.Hudlicky has also formed a partnership with McMaster University chemistry professor James McNulty to develop more compounds that can be used in effective cancer treatment, efficient pro-drug design, and other commercial uses.McNulty has developed techniques for the isolation of naturally occurring compounds in high yield and also semi-synthesis from natural intermediates and total synthesis of selected alkaloids. In addition to the discovery of compounds that exhibit potent anticancer activity, the Amaryllidaceae framework has allowed the discovery of congeners with potent and selective antiviral activity, for example to herpes viruses (HSV-1 and VZV) and one of the most active compounds reported to date against the Zika virus.McNulty and Hudlicky together have more than 50 years of experience in the isolation, synthesis and modification of Amaryllidaceae alkaloids. The discovery of other valuable biological activities is under active investigation including many other biomedical and agrochemical applications.